Skip to main content

NOVO NORDISK A/S & ANR vs. SAJJALA BIO LABS PRIVATE LIMITED. CS (COMM) 394/2019

A suit was filed seeking a permanent injunction restraining infringement of suit patent nos. 257402 and 257528. The Plaintiff alleged that the suit patents related to a novel and unique formulation of the molecule ‘LIRAGLUTIDE’ and a process thereof. On acquiring knowledge that the Defendant was planning to launch ‘LIRAGLUTIDE’ in a formulation that would be infringing the Plaintiff’s patents, the suit was filed seeking a permanent injunction and other reliefs.

On 2 August 2019, the Defendant entered appearance and sought time. In the interregnum, the parties explored an amicable resolution in view of the stand taken by the Defendant.

Ld. Counsel for the Defendant further submitted that it was not the intention of the Defendant to infringe upon any of the suit patents being IN 257402 and IN 257528.

Accordingly, the Plaintiff, upon the Defendant’s assurances, did not press for rendition of accounts or other reliefs so long as the undertaking of the Defendant was recorded that they shall not infringe the suit patents IN 257402 and IN 257528.

On 6 August 2019, the Hon’ble High Court of Delhi decreed the suit on the basis of the following terms and conditions which were mutually agreed upon by the parties:

  • That the Defendant undertakes not to manufacture, use, offer for sale or sell any formulation of ‘LIRAGLUTIDE’ or use a process for manufacture thereof, which constitutes an infringement of Suit patent nos. IN 257402 and IN 257528;
  • The above undertaking shall not in any manner preclude the Defendant from manufacture or sale of the API ‘LIRAGLUTIDE’ so long as the same is a non-infringing formulation or process;
  • In view of the above undertakings given by the Defendant, the Plaintiff does not press for the relief of rendition of accounts or damages;
  • The Defendant assures the Court that it does not have any stock of infringing ‘LIRAGLUTIDE’ products.

Further, in view of the suit having been settled at the inception itself, 50% of the Court fee was directed to be refunded to the Plaintiff.

While there may be cases with a pressing lack for speedy disposal but decrees such as these demonstrate how depending on resolution efforts, matters may be promptly disposed of.

Team Anand and Anand: Pravin Anand, Archana Shanker, Dhruv Anand, Udita M Patro and Kavya Mammen.

Most Recent

News & Insights

VIEW ALL
News & Updates
Nov 15, 2025

APPA president Hari Subramaniam congratulates Pravin Anand for receivng the APPA Enduring Impact Award in Kuala Lumpur. ‘First published on India Business

IP expert Pravin Anand honoured with prestigious APAA award
Thought Leadership
Nov 15, 2025

‘First published on Enterprise IT World’ By: Subroto Kumar Panda If you are using a phone, chances are you’ve been bombarded by calls like these:

Tired of Spam Calls? How the DPDP Rules, 2025 Put You Back in Control. The Daily Nuisance We All Know
News & Updates
Nov 04, 2025

In a remarkable conclusion to one of India’s longest-running trademark disputes, the order authored by Justice Sanjeev Narula of the Hon’ble High Court

DELHI HIGH COURT BRINGS 25-YEAR “CELEBRATIONS” TRADEMARK DISPUTE TO A WHOLESOME CLOSE
News & Updates
Nov 02, 2025

Partner Litigation, Dhruv Anand, spoke to Times of India for its dive-deep article on ‘Stars v AI’ giving a 360 degree roundup of what actually makes

Stars vs AI: Dhruv Anand speaks to ToI about personality rights and the intent behind protecting them